Acadia Healthcare Company Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
ACHC$38.64+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| (In thousands) | ||
| Operating activities: | ||
| Net income | $78,770 | $66,558 |
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: | ||
| Depreciation and amortization | 36,347 | 31,569 |
| Amortization of debt issuance costs | 1,016 | 824 |
| Equity-based compensation expense | 8,678 | 7,629 |
| Deferred income taxes | 17,476 | 212 |
| Other | (4,094) | 1,089 |
| Change in operating assets and liabilities, net of effect of acquisitions: | ||
| Accounts receivable, net | (22,930) | (23,968) |
| Other current assets | (15,629) | (23,430) |
| Other assets | 696 | (1,436) |
| Accounts payable and other accrued liabilities | (403,340) | 13,633 |
| Accrued salaries and benefits | (25,024) | (30,386) |
| Other liabilities | 6,749 | 2,114 |
| Net cash (used in) provided by operating activities | (321,285) | 44,408 |
| Investing activities: | ||
| Cash paid for acquisitions, net of cash acquired | (50,353) | — |
| Cash paid for capital expenditures | (142,410) | (66,525) |
| Proceeds from sale of property and equipment | 9,056 | 409 |
| Other | (907) | (794) |
| Net cash used in investing activities | (184,614) | (66,910) |
| Financing activities: | ||
| Borrowings on long-term debt | 350,000 | — |
| Borrowings on revolving credit facility | 160,000 | 40,000 |
| Principal payments on revolving credit facility | (15,000) | — |
| Principal payments on long-term debt | (10,242) | (5,313) |
| Payment of debt issuance costs | (1,518) | — |
| Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises | (1,013) | (47,671) |
| Contributions from noncontrolling partners in joint ventures | 2,280 | 1,655 |
| Distributions to noncontrolling partners in joint ventures | (1,020) | — |
| Other | (358) | 11 |
| Net cash provided by (used in) financing activities | 483,129 | (11,318) |
| Net decrease in cash and cash equivalents | (22,770) | (33,820) |
| Cash and cash equivalents at beginning of the period | 100,073 | 97,649 |
| Cash and cash equivalents at end of the period | $77,303 | $63,829 |
| Effect of acquisitions: | ||
| Assets acquired, excluding cash | $55,309 | $— |
| Liabilities assumed | (3,456) | — |
| Contingent consideration issued in connection with an acquisition | (1,500) | — |
| Cash paid for acquisitions, net of cash acquired | $50,353 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.